.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,385,907

« Back to Dashboard

Claims for Patent: 5,385,907

Title: Ointments containing FK-506 or derivatives thereof
Abstract:An ointment comprising a tricyclic compound such as FK 506 substance which is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1 .0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone, or the like, a solubilizing and/or absorption-promoting agent and an ointment base, which is useful for treating various skin diseases.
Inventor(s): Asakura; Sotoo (Kyoto, JP), Murakami; Yoshio (Kobe, JP), Kanagawa; Nobuto (Takaoka, JP), Nakate; Toshiomi (Kobe, JP)
Assignee: Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:08/062,330
Patent Claims: 1. An ointment consisting essentially of a tricyclic compound represented by the following formula (I): ##STR4## wherein each of adjacent pairs of R.sup.1 and R.sup.2, R.sup.3 and R.sup.4 or R.sup.5 and R.sup.6 independently is

(a) two adjacent hydrogen atoms, or

(b) may form another bond formed between the carbon atoms to which they are attached,

and further, R.sup.2 is an alkyl group;

R.sup.7 is a hydrogen atom, a hydroxy group, a protected hydroxy group or an alkoxy group, or an oxo group together with R.sup.1 ; R.sup.8 and R.sup.9 each is independently a hydrogen atom or a hydroxy group;

R.sup.10 is a hydrogen atom, and alkyl group, an alkyl group substituted by one or more hydroxy groups, an alkenyl group, an alkenyl group substituted by one or more hydroxy groups or an alkyl group substituted by an oxo group;

X.sup.1 is a hydrogen atom or a hydroxy group;

X.sup.2 is a hydrogen atom; or

X.sup.1 and X.sup.2 may together represent an oxo group or --CH.sub.2 O--;

Y.sup.1 is a hydrogen atom or a hydroxy group;

Y.sup.2 is a hydrogen atom; or

Y.sup.1 and Y.sup.2 may together represent an oxo group, ##STR5## R.sup.11 and R.sup.12 each is independently a hydrogen atom, an alkyl group, an aryl group or a tosyl group; R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.22 and R.sup.23 each is independently a hydrogen atom or an alkyl group;

R.sup.20 and R.sup.21 each is an oxo group or independently (R.sup.20 a and a hydrogen atom) or (R.sup.21 a and a hydrogen atom) in which R.sup.20 a and R.sup.21 a each is a hydroxy group, an alkoxy group or a group represented by the formula --OCH.sub.2 OCH.sub.2 CH.sub.2 OCH.sub.3, or R.sup.21 a is a protected hydroxy group, or R.sup.2 a and R.sup.2 a may together represent an oxygen atom in an epoxide ring;

n is an integer of 1, 2 or 3;

in addition to their above definitions, four of Y.sup.1, Y.sup.2, R.sup.10 and R.sup.23, together with the carbon atoms to which they are attached, may represent a saturated or unsaturated 5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring optionally substituted by one or more groups selected from the group consisting of an alkyl, a hydroxy, an alkyl substituted by one or more hydroxy, an alkoxy, benzyl and a group of the formula --CH.sub.2 Se(C.sub.6 H.sub.5);

or a pharmaceutically acceptable salt thereof, a solubilizing and/or absorption-promoting agent selected from the group consisting of a lower alkanediol, a lower alkylene carbonate, an alkane dicarboxylic ester, a higher alkane carboxylic glycerin ester, a higher alkene carboxylic glycerin ester, a higher alkane carboxylic alkyl ester, a higher unsaturated alcohol and an azacycloalkane, and an ointment based selected from the group consisting of oil and fat bases;

in which the tricyclic compound (I) or a pharmaceutically acceptable salt thereof is contained therein in an amount of about 0.01 to 10% (w/w), and the solubilizing and/or absorption-promoting agent is contained therein in an amount of about 1 to 30% (w/w),

where optionally is present one or more of the following ingredients selected from the group consisting of colorants, preservatives, and higher alkene carboxylic acids.

2. An ointment as claimed in claim 1 in which the solubilizing and/or absorption-promoting agent is a lower alkanediol, a lower alkylene carbonate or an alkane dicarboxylic ester.

3. An ointment as claimed in claim 1 in which the tricyclic compound (I) is the one wherein each of adjacent pairs of R.sup.3 and R.sup.4 or R.sup.5 and R.sup.6 independently may form another bond formed between the carbon atoms to which they are attached,

R.sup.8 and R.sup.23 each is independently a hydrogen atom;

R.sup.9 is a hydroxy group;

R.sup.10 is methyl, ethyl, propyl or allyl;

X.sup.1 is a hydrogen atom;

X.sup.2 is a hydrogen atom; or

X.sup.1 and X.sup.2 may together represent an oxo group;

Y.sup.1 and Y.sup.2 may together represent an oxo group;

R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19 and R.sup.22 each is independently methyl;

R.sup.20 and R.sup.21 independently are (R.sup.20 a and a hydrogen atom) or (R.sup.21 a and a hydrogen atom) in which R.sup.20 a and R.sup.21 a each is a hydroxy group or an alkoxy group or R.sup.21 a is a protected hydroxy group; and

n is an integer of 1 or 2.

4. An ointment as claimed in claim 3 in which the tricyclic compound (I) is the one wherein R.sup.7 is a hydrogen atom, a hydroxy group or a protected hydroxy group;

X.sup.1 and X.sup.2 may together represent an oxo group;

R.sup.20 a is methoxy; and

R.sup.21 a is a hydroxy or protected hydroxy group.

5. An ointment as claimed in claim 4 in which the tricyclic compound (I) is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3. 1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.

6. An ointment as claimed in claim 4 in which the tricyclic compound (I) is 17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3. 1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.

7. An ointment of claim 1, wherein at least one of said ingredients selected from the group consisting of perfumes, colorants, preservatives, and higher alkene carboxylic acids is present.

8. An ointment as claimed in claim 2 in which the tricyclic compound (I) is the one wherein each of adjacent pairs of R.sup.3 and R.sup.4 or R.sup.5 and R.sup.6 independently may form another bond formed between the carbon atoms to which they are attached,

R.sup.8 and R.sup.23 each is independently a hydrogen atom;

R.sup.9 is a hydroxy group;

R.sup.10 is methyl, ethyl, propyl or allyl;

X.sup.1 is a hydrogen atom;

X.sup.2 is a hydrogen atom; or

X.sup.1 and X.sup.2 may together represent an oxo group;

Y.sup.1 and Y.sup.2 may together represent an oxo group;

R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19 and R.sup.22 each is independently methyl;

R.sup.20 and R.sup.21 independently are (R.sup.20 a and a hydrogen atom) or (R.sup.21 a and a hydrogen atom) in which R.sup.20 a and R.sup.21 a each is a hydroxy group or an alkoxy group or R.sup.21 a is a protected hydroxy group; and

n is an integer of 1 or 2.

9. An ointment as claimed in claim 8 in which the tricyclic compound (I) is the one wherein R.sup.7 is a hydrogen atom, a hydroxy group or a protected hydroxy group;

X.sup.1 and X.sup.2 may together represent an oxo group;

R.sup.20 a is a methoxy; and

R.sup.21 a is a hydroxy or protected hydroxy group.

10. An ointment as claimed in claim 9 in which the tricyclic compound (I) is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylv inyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22 .3.1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.

11. An ointment as claimed in claim 9 in which the tricyclic compound (I) is 17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylv inyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22 .3.1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.

12. An ointment as claimed in claim 1 consisting of a tricyclic compound represented by the following formula (I): ##STR6## wherein each of adjacent pairs of R.sup.1 and R.sup.2, R.sup.3 and R.sup.4 or R.sup.5 and R.sup.6 independently is

(a) two adjacent hydrogen atoms, or

(b) may form another bond formed between the carbon atoms to which they are attached, and further, R.sup.2 is an alkyl group;

R.sup.7 is a hydrogen atom, a hydroxy group, a protected hydroxy group or an alkoxy group, or an oxo group together with R.sup.1 ;

R.sup.8 and R.sup.9 each is independently a hydrogen atom or a hydroxy group;

R.sup.10 is a hydrogen atom, an alkyl group, an alkyl group substituted by one or more hydroxy groups, an alkenyl group, an alkenyl group substituted by one or more hydroxy groups or an alkyl group substituted by an oxo group;

X.sup.1 is a hydrogen atom or a hydroxy group;

X.sup.2 is a hydrogen atom; or

X.sup.1 and X.sup.2 may together represent an oxo group or --CH.sub.2 O--;

Y.sup.1 is a hydrogen atom or a hydroxy group;

Y.sup.2 is a hydrogen atom; or

Y.sup.1 and Y.sup.2 may together represent an oxo group, ##STR7## R.sup.11 and R.sup.12 each is independently a hydrogen atom, an alkyl group, an aryl group or a tosyl group;

R.sup.13 R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.22 and R.sup.23 each is independently a hydrogen atom or an alkyl group;

R.sup.20 and R.sup.21 each is an oxo group or independently (R.sup.20 a and a hydrogen atom) or (R.sup.21 a and a hydrogen atom) in which R.sup.20 a and R.sup.21 a each is a hydroxy group, an alkoxy group or a group represented by the formula --OCH.sub.2 OCH.sub.2 CH.sub.2 OCH.sub.3, or R.sup.21 a is a protected hydroxy group, or R.sup.20 a and R.sup.21 a may together represent an oxygen atom in an epoxide ring;

n is an integer of 1, 2 or 3;

in addition to their above definitions, four of Y.sup.1, Y.sup.2, R.sup.10 and R.sup.23, together with the carbon atoms to which they are attached, may represent a saturated or unsaturated 5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring optionally substituted by one or more groups selected from the group consisting of an alkyl, a hydroxy, an alkyl substituted by one or more hydroxy, an alkoxy, benzyl and a group of the formula --CH.sub.2 Se(C.sub.6 H.sub.5); or a pharmaceutically acceptable salt thereof, a solubilizing and/or absorption-promoting agent selected from the group consisting of a lower alkanediol, a lower alkylene carbonate, an alkane dicarboxylic ester, a higher alkane carboxylic glycerin ester, a higher alkene carboxylic glycerin ester, a higher alkane carboxylic alkyl ester, a higher unsaturated alcohol and an azacycloalkane, and an ointment base selected from the group consisting of oil and fat bases;

in which the tricyclic compound (I) or a pharmaceutically acceptable salt thereof is contained therein in an amount of about 0.01 to 10% (w/w), and the solubilizing and/or absorption-promoting agent is contained therein in an amount of about 1 to 30% (w/w).

13. An ointment as claimed in claim 1, wherein said oil and fat bases are selected from the group consisting of natural waxes, petroleum waxes, higher aliphatic acid glycerin esters, hydrocarbons, and mixtures thereof.

14. An ointment as claimed in claim 12, wherein said oil and fat bases are selected from the group consisting of natural waxes, petroleum waxes, higher aliphatic acid glycerin esters, hydrocarbons, and mixtures thereof.

15. An ointment as claimed in claim 1, wherein said ointment base consists of white petrolatum, solid paraffin, liquid paraffin and white beeswax and wherein said solubilizing and/or absorption-promoting agent is selected from the group consisting of propylene carbonate alone or in combination with diisopropyl adipate.

16. An ointment as claimed in claim 12, wherein said ointment base consists of white petrolatum, solid paraffin, liquid paraffin and white beeswax and wherein said solubilizing and/or absorption-promoting agent is selected from the group consisting of propylene carbonate alone or in combination with diisopropyl adipate.

17. An ointment as claimed in claim 1, in which the tricyclic compound represented by formula (I) is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3. 1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.

18. The ointment as claimed in claim 17, wherein said solubilizing and/or absorption-promoting agent is a lower alkylene carbonate.

19. The ointment as claimed in claim 18, wherein said lower alkylene carbonate is propylene carbonate.

20. An ointment as claimed in claim 12, in which the tricyclic compound represented by formula (I) is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3. 1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.

21. The ointment as claimed in claim 20, wherein said solubilizing and/or absorption-promoting agent is a lower alkylene carbonate.

22. The ointment as claimed in claim 21, wherein said lower alkylene carbonate is propylene carbonate.

23. An ointment as claimed in claim 15, wherein said solubilizing and/or absorption-promoting agent is propylene carbonate and wherein said tricyclic compound represented by formula (I) is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3. 1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.

24. An ointment as claimed in claim 16, wherein said solubilizing and/or absorption-promoting agent is propylene carbonate and wherein said tricyclic compound represented by formula (I) is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3. 1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc